WASHINGTON, D.C. (February 18, 2005) -- The administrator of the Centers for Medicare and Medicaid Services (CMS), Mark B. McClellan, M.D., Ph.D., will give a keynote address at the seventh annual Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York City next week.
Dr. McClellan will discuss CMS actions and policies that affect the biotechnology industry, including implementation of the landmark Medicare Modernization Act, which will provide voluntary prescription coverage to the nation’s seniors and the disabled beginning in January 2006.
Dr. McClellan’s keynote address is scheduled on Wednesday, February 23, from 5:30 to 6:15 pm in the Astor Salon of the Waldorf=Astoria.
The BIO CEO & Investor Conference is the premier biotechnology investor event with more than 200 presenting companies from the U.S., Europe and Canada. The conference will feature focused panel discussions with company executives along with clinical, financial and regulatory experts who will present their views on the most promising developments in medical biotechnology for diseases and medical conditions such as hepatitis, lupus, cancer, HIV, diabetes and eye disorders. Industry experts will hold roundtable discussions on hot-button business issues affecting the industry including commercialization strategies, value creation and emerging regulations from the Food and Drug Administration as well the Securities and Exchange Commission. One-on-one meetings will be arranged between investors and corporate management.
For more information about BIO CEO & Investor Conference 2005, please visit www.ceo.bio.org Registration is complimentary for credentialed news media and investors. Online registration has expired for media. On-site registration will be open only to reporters and editors working full-time for print or broadcast news organizations with valid media credentials.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in 31 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.